Oryzon assigns Dr. Xavier Luria as Non-Executive Director of Medical and Regulatory Affairs

 

Dr. Luria is a renowned expert in the clinical development of pharmaceuticals and has been Senior Executive of the European Medicines Agency (EMA).

The collaboration is focused on the clinical development of Oryzon’s selective LSD1 inhibitor for the treatment of acute leukemia.

The company will present its LSD1 inhibitor program on hematological cancers at the annual Bio-2012 International Convention, which takes place on June 18-21 in Boston.

Oryzon announces the incorporation to its expert’s team of Dr. Xavier Luria as Non-Executive Director of Medical and Regulatory Affairs.

Dr. Luria had been Head of Sector for Safety and Efficacy of Medicines at the European Medicines Agency for almost 7 years and is a renowned international expert in the clinical development of drugs.

Click here to see full Press Release.